Q-omics provides the consensus-scored GLYATL1B profile across patient tissues and cancer cell-line models. GLYATL1B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, GLYATL1B is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, GLYATL1B RNA expression shows 13,279 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight THCA, KICH, and DLBC as cancer lineages where GLYATL1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLYATL1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLYATL1B survival associations across molecular data types. GLYATL1B RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLYATL1B RNA expression–survival associations across cancer types. High GLYATL1B expression shows unfavorable associations in THCA, COAD, PCPG, KIRC and SKCM, but favorable associations in OV. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for GLYATL1B RNA expression.
This table summarizes GLYATL1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GLYATL1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLYATL1B shows higher tumor expression in KICH, KIRC, LUAD, ESCA, KIRP and PRAD. The KICH box plot shows higher GLYATL1B RNA expression in tumor versus normal tissue (log2 FC = +0.316, t-test p < 0.001).
This table shows molecular features associated with GLYATL1B in patient tissues and cancer cell lines. In patient samples, GLYATL1B shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, GLYATL1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma.
